Skip to main content
Premium Trial:

Request an Annual Quote

Rarity Bioscience Raises Additional €500,000

NEW YORK — Swedish molecular diagnostics startup Rarity Bioscience said on Monday that it has raised a €500,000 ($537,908) as part of an oversubscription of an earlier €2.5 million seed financing round.

The latest investment came from venture capital firm Novalis Biotech. The seed round, which closed in November, was led by Rarity founders and Wallenberg Investments' Navigare Ventures.

Rarity was formed as a spinout of Uppsala University in 2021 to develop and commercialize a technology, called SuperRCA, that uses consecutive rolling circle amplification reactions to enable the detection of ultra-low levels of cell-free and genomic DNA in tissue and blood samples. Assays that use the technology can detect multiple targets simultaneously, according to the company.

In mid-2022, Rarity cofounders published data in Nature Communications demonstrating the use of technology for monitoring leukemia patients' disease and response to treatment.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.